Overview
Melanotan II is “a synthetic analog of α-melanocyte-stimulating hormone studied for its ability to increase skin pigmentation” and noted for inducing erectile activity as a side effect. Early human trials identified effective daily doses between 1–2 mg for tanning, with conservative protocols starting lower to minimize adverse reactions such as nausea and flushing.
Quick Start
– Reconstitution: Add 3.0 mL bacteriostatic water to create a 3.33 mg/mL concentration
– Daily range: 250–1000 mcg once daily via gradual titration over 8–12 weeks
– Measurement: At 3.33 mg/mL, 1 unit on a U-100 insulin syringe ≈ 33.3 mcg
– Storage (lyophilized): −20 °C (−4 °F) or colder; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for 1–2 weeks
Dosing & Reconstitution Guide
Standard Gradual Titration (3 mL dilution)
| Week/Phase | Daily Dose | Units (U-100 syringe) | Volume (mL) |
|---|---|---|---|
| Week 1 | 250 mcg | 7.5 units | 0.075 mL |
| Week 2 | 500 mcg | 15 units | 0.15 mL |
| Week 3 | 750 mcg | 22.5 units | 0.225 mL |
| Weeks 4–8 | 1000 mcg | 30 units | 0.30 mL |
| Maintenance (post-Week 8) | 500–1000 mcg, 1–2× weekly | 15–30 units | 0.15–0.30 mL |
Reconstitution Steps
1. Draw 3.0 mL bacteriostatic water with a sterile syringe
2. Inject slowly down the vial wall to avoid foaming; do not shake vigorously
3. Gently roll or swirl until fully dissolved
4. Label with reconstitution date
5. Store refrigerated at 2–8 °C (35.6–46.4 °F), protected from light
Supplies Needed
For 8-week daily protocol with gradual titration:
– Peptide vials: Approximately 5 vials (45–50 mg total)
– U-100 insulin syringes: 56 syringes (7 per week)
– Bacteriostatic water: 15 mL total (2 × 10 mL bottles)
– Alcohol swabs: 112 swabs (2 per day); recommend 2 × 100-count boxes
For 12-week protocol: multiply by approximately 1.5; for 16 weeks: multiply by 2.
Protocol Overview
– Goal: Increase skin pigmentation through melanocortin receptor activation, even without UV exposure
– Schedule: Daily subcutaneous injections for 6–8 weeks (loading phase), then maintenance dosing 1–2× weekly
– Frequency: Once per day during loading phase; rotate injection sites to reduce irritation
– Cycle length: 6–8 weeks initial tanning, then transition to maintenance
– Maintenance: 500–1000 mcg administered 1–2× weekly to sustain pigmentation
How It Works
Melanotan II is “a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone that binds to melanocortin receptors, particularly MC1R and MC4R.” Activation of MC1R on melanocytes stimulates melanin production and distribution, resulting in increased skin pigmentation without UV exposure. “Measurable tanning [was] observed after just five low doses administered over two weeks” in Phase I human studies, with effects accumulating during daily injections.
Lifestyle Factors
– UV exposure: While Melanotan II increases melanin without UV, some users combine with minimal UV exposure; always use sun protection to reduce skin cancer risk
– Hydration: Maintain adequate fluid intake, especially if experiencing nausea or appetite suppression
– Monitoring: Inspect moles and skin regularly for changes; seek dermatological evaluation if new or changing lesions appear
– Dose discipline: Never exceed 2 mg per day to avoid serious adverse effects
Potential Benefits
– Increases skin pigmentation (tanning) without UV exposure requirement
– Tanning effects observable after 5–10 daily injections in most individuals
– May induce spontaneous erections in men as a noted side effect
– Maintenance dosing (1–2× weekly) can sustain pigmentation after initial loading phase
Common Side Effects
– Nausea (dose-dependent; most common at higher doses)
– Facial flushing and increased skin warmth
– Reduced appetite and mild fatigue
– Spontaneous erections or increased libido in men
– Injection site reactions (redness, mild stinging)
Serious Risks & Warnings
– Not FDA-approved: Melanotan II carries regulatory and safety risks
– Dose-limiting toxicity: Severe sympathomimetic symptoms and rhabdomyolysis reported at 6 mg dose
– Mole changes: May alter pigmentation of existing moles; theoretical melanoma concerns warrant caution
– Cardiovascular effects: Transient increases in heart rate and blood pressure possible at higher doses
– Never exceed 2 mg per day
Injection Technique
– Clean vial stopper and injection site with alcohol swabs; allow both to air dry completely
– Use 1 mL insulin syringe (29–31 gauge, ½ inch needle) for subcutaneous administration
– Pinch a fold of skin approximately 1 inch thick at injection site (abdomen preferred, at least 2 inches from navel)
– Insert needle at 45–90° depending on body composition; release pinch after needle insertion
– Do not aspirate for subcutaneous injections; inject slowly and steadily
– Withdraw needle at same angle; apply gentle pressure with clean gauze if needed
– Rotate sites systematically to avoid lipohypertrophy or scarring
– Dispose of used syringes immediately in a proper sharps container; never reuse needles
Important Notes
– Use new sterile insulin syringes for each injection; dispose in sharps container immediately
– Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and scarring
– Clean vial stopper and injection site with alcohol swabs before each use; allow to air dry
– Inject slowly and steadily; wait a few seconds before withdrawing the needle
– Document daily dose, injection site, and any side effects to maintain consistency and track tolerance
– Case reports document “serious systemic toxicity and rhabdomyolysis at mega-doses (6 mg)”
Disclaimer
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Melanotan II is not an approved medication by the FDA or other regulatory agencies. Research use only; not for human consumption. Any use carries significant risks including potential serious adverse effects. Consult qualified healthcare professionals before considering any peptide research.